{(S)-6-[(R)-4-(1-oxa-8-azaspiro[4.5]dec-8-ylmethyl)-5-trifluoromethylindan-1-yloxy]-2,3-dihydrobenzofuran-3-yl}acetic acid methyl ester | 1621168-59-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂螺癸烷衍生物
• 英文名称: {(S)-6-[(R)-4-(1-oxa-8-azaspiro[4.5]dec-8-ylmethyl)-5-trifluoromethylindan-1-yloxy]-2,3-dihydrobenzofuran-3-yl}acetic acid methyl ester
• 英文别名: {(S)-6-[(R)-4-(1-Oxa-8-aza-spiro[4.5]dec-8-ylmethyl)-5-trifluoromethyl-indan-1-yloxy]-2,3-dihydro-benzofuran-3-yl}-acetic acid methyl ester；methyl 2-[(3S)-6-[[(1R)-4-(1-oxa-8-azaspiro[4.5]decan-8-ylmethyl)-5-(trifluoromethyl)-2,3-dihydro-1H-inden-1-yl]oxy]-2,3-dihydro-1-benzofuran-3-yl]acetate
• CAS: 1621168-59-9
• 化学式: C₃₀H₃₄F₃NO₅
• 分子量: 545.599
• InChiKey: CCZVPRUHJBIKEN-NIYFSFCBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  39
• 可旋转键数：
  7
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  57.2
• 氢给体数：
  0
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  N-(trifluoroboratomethyl)thiomorpholine internal salt 、 {(S)-6-[(R)-4-(1-oxa-8-azaspiro[4.5]dec-8-ylmethyl)-5-trifluoromethylindan-1-yloxy]-2,3-dihydrobenzofuran-3-yl}acetic acid methyl ester 在 palladium diacetate 、 caesium carbonate 、 2-二环己基磷-2,4,6-三异丙基联苯 作用下， 以 四氢呋喃 、 水 为溶剂， 生成 {(S)-6-[(R)-4-thiomorpholin-4-ylmethyl-5-trifluoromethylindan-1-yloxy]-2,3-dihydrobenzofuran-3-yl}acetic acid methyl ester
  参考文献：
  名称：

  INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS

  摘要：

  通式I的化合物，其中基团R1如权利要求1所定义，具有有价值的药理学特性，特别是结合GPR40受体并调节其活性。这些化合物适用于治疗和预防可以受到该受体影响的疾病，例如代谢性疾病，特别是2型糖尿病。

  公开号：

  US20140221349A1
• 作为产物：
  描述：

  {(S)-6-[(R)-4-bromo-5-trifluoromethyl-indan-1-yloxy]-2,3-dihydro-benzofuran-3-yl}-acetic acid methyl ester 、 (1-oxa-8-azoniaspiro[4.5]dec-8-yl)methyltrifluoroborate 、 生成 {(S)-6-[(R)-4-(1-oxa-8-azaspiro[4.5]dec-8-ylmethyl)-5-trifluoromethylindan-1-yloxy]-2,3-dihydrobenzofuran-3-yl}acetic acid methyl ester
  参考文献：
  名称：

  Indanyloxydihydrobenzofuranylacetic acids

  摘要：

  通式I的化合物，其中基团R1如权利要求1所定义，具有有价值的药理学特性，特别是与GPR40受体结合并调节其活性。这些化合物适用于治疗和预防可以受该受体影响的疾病，例如代谢性疾病，特别是2型糖尿病。

  公开号：

  US08927531B2

文献信息

• NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP2953681A1

  公开（公告）日：2015-12-16
• US8927531B2
  申请人：——

  公开号：US8927531B2

  公开（公告）日：2015-01-06
• [EN] NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS<br/>[FR] NOUVEAUX ACIDES INDANYLOXYDIHYDROBENZOFURANYLACÉTIQUES
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2014122067A1

  公开（公告）日：2014-08-14

  The present invention relates to compounds of general formula I, (I) wherein the group R1 is defined as in claim 1, which have valuable pharmacological properties, in particular bind to the G-protein coupled receptor 40 (GPR40, also known as free fatty acid receptor FFAR 1) and modulate its activity. The compounds are suitable for the treatment and prevention of diseases which can be influenced by this receptor; metabolic diseases, such as diabetes, more specifically type 2 diabetes mellitus, and conditions associated with the disease, including insulin resistance, obesity, cardiovascular disease and dyslipidemia.
• INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS
  申请人：ECKHARDT Matthias

  公开号：US20140221349A1

  公开（公告）日：2014-08-07

  Compounds of general formula I wherein the group R 1 is defined as in claim 1 , which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.

  通式I的化合物，其中基团R1如权利要求1所定义，具有有价值的药理学特性，特别是结合GPR40受体并调节其活性。这些化合物适用于治疗和预防可以受到该受体影响的疾病，例如代谢性疾病，特别是2型糖尿病。
• Indanyloxydihydrobenzofuranylacetic acids
  申请人：Eckhardt Matthias

  公开号：US08927531B2

  公开（公告）日：2015-01-06

  Compounds of general formula I wherein the group R1 is defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.

  通式I的化合物，其中基团R1如权利要求1所定义，具有有价值的药理学特性，特别是与GPR40受体结合并调节其活性。这些化合物适用于治疗和预防可以受该受体影响的疾病，例如代谢性疾病，特别是2型糖尿病。